Regulatory approval

Published by the Health Canada. Approved

VECTIBIX (panitumumab for injection) is indicated for the treatment of previously untreated patients with non-mutated (wild-type) RAS metastatic colorectal carcinoma (mCRC) in combination with FOLFOX (infusional 5-fluorouracil, leucovorin, and oxaliplatin).

This is written in the approval document.

Citation

Amgen Canada Inc. Vectibix (panitumumab)[product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00063326.PDF. Revised October 2021. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description